TabsDetailsBasic DetailsDate: Tuesday, August 23, 2016Type: PresentationMedical Product: angiotensin-converting enzyme (ACE) inhibitorHealth Outcome(s): angioedemaMaterials: Assessment of the US Food and Drug Administration’s Sentinel Analysis Tools: Angiotensin-Converting Enzyme Inhibitors and AngioedemaAdditional InformationInformationHost: 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk ManagementRelated Assessment(s): Abstracts of the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, The Convention Centre Dublin, Dublin, Ireland August 25–28, 2016ContributorsPresenter(s): Joshua Gagne
